Genes, Cost-Effectiveness and Healthcare Reform – Dialog with Dr. Buchanan

This is a posting of my reply to British health economist Dr. Buchanan's Comment of February 17, 2018.  The original posts are: Medicines's future? The health economics of population-wide genomic screening (October 26, 2017) Cost-Effectiveness: From Genes to Healthcare System Reform (December 17, 2017) 2 thoughts on “Cost-Effectiveness: From Genes to Healthcare System Reform” (Reply, February … Continue reading Genes, Cost-Effectiveness and Healthcare Reform – Dialog with Dr. Buchanan

Cost-Effectiveness: From Genes to Healthcare System Reform

British health economist James Buchanan D.Phil. is skeptical that Geisinger Health System’s (Pa.) genomics project will prove to be cost-effective. But what about the cost-effectiveness of the whole U.S. health system? As a physician and resident of the southern reaches of Geisinger Health System’s catchment area in central Pennsylvania, I was intrigued by Dr. Buchanan’s … Continue reading Cost-Effectiveness: From Genes to Healthcare System Reform